PT - JOURNAL ARTICLE AU - Vladimir Shnaydman TI - Simulation model for productivity, risk and GDP impact forecasting of the COVID-19 portfolio vaccines AID - 10.1101/2020.11.01.20214122 DP - 2020 Jan 01 TA - medRxiv PG - 2020.11.01.20214122 4099 - http://medrxiv.org/content/early/2020/11/04/2020.11.01.20214122.short 4100 - http://medrxiv.org/content/early/2020/11/04/2020.11.01.20214122.full AB - The paper presents the methodology and modeling results for COVID-19 vaccines portfolio forecasting, including R&D output (rate and likelihood of approvals at a vaccine technology platform level) and manufacturing production output to meet worldwide demand.In order to minimize the time and risk of global vaccination, scaling up of Operation Warp Speed (OWS) and other programs could be very beneficial, leading to increased financing for additional vaccine development programs, in both Phase III clinical trials and in manufacturing. It would also lead to a reduction of the global production time for world vaccination, from 75 months for a baseline scenario to 36 months, reducing potential global GDP loss by as much as US$4.2 trillion (US ∼ $1 trillion) when compared to the baseline scenario.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:N/AAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is available